Key Takeaway: Werewolf Therapeutics, Inc. released its financial results for the first quarter of 2024, along with a business update. The report was published on May 3, 2024, from Watertown, Massachusetts. Further details regarding the financial performance and business strategies were not provided in the article.
Price reaction · baseline $6.08 (2024-05-02 close) · hit pre-market · clean, no other HOWL news in the window
day 0 close
-0.2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
15%
average across 6 past catalysts
Lead asset
WTX-330
Phase 1 · Advanced or Metastatic Solid Tumors
Full Press Release Details
May 3, 2024
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
WATERTOWN, Mass., May 03, 2024 -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)